Next Article in Journal
Macrophages and Cell-Cell Spread of HIV-1
Next Article in Special Issue
Cyclophilin Inhibitors as a Novel HCV Therapy
Previous Article in Journal
A VSV-G Pseudotyped Last Generation Lentiviral Vector Mediates High Level and Persistent Gene Transfer in Models of Airway Epithelium In Vitro and In Vivo
Previous Article in Special Issue
Targeting microRNA-122 to Treat Hepatitis C Virus Infection
Viruses 2010, 2(8), 1589-1602; doi:10.3390/v2081589

Interferon-λ in HCV Infection and Therapy  

Department of Pathology, Yale University School of Medicine, New Haven, CT 06510, USA
* Author to whom correspondence should be addressed.
Received: 28 June 2010 / Accepted: 28 July 2010 / Published: 5 August 2010
(This article belongs to the Special Issue Antivirals Against Hepatitis C Virus)
View Full-Text   |   Download PDF [207 KB, uploaded 12 May 2015]   |  


Chronic infection with hepatitis C virus (HCV) is associated with significant liver disease and is therefore an important public health problem. The current standard-of-care therapy for chronic HCV infection consists of a combination of pegylated (PEG) interferon (IFN)-α and ribavirin. Although this therapy effectively generates a sustained viral response in approximately half of treated individuals, it is associated with significant hematological and neurological side effects. A new family of IFN-related proteins (IFN-λ1, 2, and 3; or alternately, IL-29, 28A, 28B, respectively) possesses properties that may make these cytokines superior to PEG-IFN-α for HCV therapy. Genetic studies have also implicated these proteins in both the natural and therapy-induced resolution of HCV infection. This review summarizes the basic aspects of IFN-λ biology, the potential role of these cytokines in HCV infection, and the outlook for their therapeutic application.
Keywords: IFN-λ; IL-28; IL-29; type III interferon; IL28B; IL-28Rα IFN-λ; IL-28; IL-29; type III interferon; IL28B; IL-28Rα
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Share & Cite This Article

Further Mendeley | CiteULike
Export to BibTeX |
EndNote |
MDPI and ACS Style

Pagliaccetti, N.E.; Robek, M.D. Interferon-λ in HCV Infection and Therapy  . Viruses 2010, 2, 1589-1602.

View more citation formats

Related Articles

Article Metrics

For more information on the journal, click here


[Return to top]
Viruses EISSN 1999-4915 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert